All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network
During the 2021 ASCO Annual Meeting, the MPN Hub spoke with Jan Philipp Bewersdorf, Yale School of Medicine, New Haven, US. We asked, Which factors may impact transplantation outcomes in patients with myelofibrosis (MF)?
Which factors may impact transplantation outcomes in patients with MF?
Bewersdorf presents results from a systematic review and meta-analysis investigating whether allo-HCT should be considered for eligible patients with MF, and the importance of risk stratification.
How to switch therapies in patients with myelofibrosis
Myelofibrosis (MF) is a heterogeneous disease with limited treatment options, which may cause treatment challenges when patients no longer respond to one therapy. Donal P. McLornan and Claire N....
The role of inflammation in MPN and its therapeutic management
Myeloproliferative neoplasms (MPN) are a group of hematological malignancies characterized by aberrant clonal expansion of hematopoietic stem cells (HSCs) in the bone marrow (BM). This...
Subscribe to get the best content related to MPN delivered to your inbox